RxDoctor Payments Data

Daniel Sims, MD

Internal Medicine · Atlanta, GANPI 1548283112

Payments from drug & device makers

$8,312in general payments, 2019–2025

Across 100 payments — averaging $83.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
  • Abbott$2K
  • Abiomed$428
  • Novartis$300
  • Merck$221
  • Actelion Pharmaceuticals US, Inc.$192
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$1,50018%
  • Speaking & faculty fees$4,00048%
  • Food & beverage$2,62832%
  • Education$1842%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,312 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$58,348
Medicare patients
105
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis15$543,340
EntrestoSacubitril/Valsartan75$78,894
EliquisApixaban53$41,773
FarxigaDapagliflozin Propanediol24$27,043
JardianceEmpagliflozin12$9,939
Metoprolol Succinate87$1,284
Potassium Chloride20$1,217
Torsemide16$511
Hydralazine Hcl19$400
Atorvastatin Calcium50$380
Spironolactone47$342
Carvedilol42$300
Warfarin Sodium25$289
Ezetimibe30$247
Digoxin15$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$176$585,11368 claims
NovartisEntresto$300$78,89475 claims
AstraZenecaFarxiga$43$27,04324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →